VANCOUVER, British Columbia – TheNewswire – July 29, 2020 — Naturally Splendid Enterprises Ltd. (“Naturally Splendid” or “NSE”) (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) is pleased to announce that the Company’s phase 2 clinical trial, as per its proposed joint venture with Biologic Pharmamedical Research for Cavaltinib(TM) (See Company news release, May 19, 2020.), has been approved for a COVID-19 clinical trial by Health Canada.

Leave a Reply

Your email address will not be published.